^
    Apply
    A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (AdvanTIG-206) (NCT04948697)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    08/20/2021
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)
    Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (AdvanTIG-203) (NCT04732494)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    01/31/2025
    Initiation :
    03/31/2021
    Primary completion :
    02/01/2023
    Completion :
    12/26/2023
    PD-L1
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer (BGB-LC-202) (NCT05577702)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    12/18/2024
    Initiation :
    02/16/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • pemetrexed • ociperlimab (BGB-A1217) • alcestobart (LBL-007)
    A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (AdvanTIG-302) (NCT04746924)
    Phase 3
    BeiGene
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    06/08/2021
    Primary completion :
    04/01/2026
    Completion :
    10/01/2026
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (AdvanTIG-205) (NCT05014815)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    11/16/2021
    Primary completion :
    10/01/2024
    Completion :
    10/01/2024
    PD-L1
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors (AdvanTIG-105) (NCT04047862)
    Phase 1
    BeiGene
    Active, not recruiting
    Last update posted :
    03/01/2024
    Initiation :
    08/26/2019
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • etoposide IV • ociperlimab (BGB-A1217)
    Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab (NCT05267054)
    Phase 1/2
    BeiGene
    Recruiting
    Last update posted :
    11/10/2023
    Initiation :
    04/25/2022
    PD-L1
    |
    Rituxan (rituximab) • Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217)
    AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer (NCT04693234)
    Phase 2
    BeiGene
    Completed
    Last update posted :
    10/27/2023
    Initiation :
    02/15/2021
    Primary completion :
    06/16/2022
    Completion :
    08/31/2023
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • mipsagargin (G-202)
    Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (AdvanTIG-211) (NCT05809895)
    Phase 2
    Novartis Pharmaceuticals
    Withdrawn
    Last update posted :
    07/24/2023
    Initiation :
    09/15/2023
    Primary completion :
    07/17/2029
    Completion :
    07/18/2029
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • ociperlimab (BGB-A1217)
    Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (AdvanTIG-306) (NCT05791097)
    Phase 3
    Novartis Pharmaceuticals
    Withdrawn
    Last update posted :
    07/24/2023
    Initiation :
    07/28/2023
    Primary completion :
    12/24/2027
    Completion :
    12/26/2027
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed • ociperlimab (BGB-A1217)